SABITU OLASUPO

Mr. SABITU OLASUPO


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Journal of the Iranian Chemical Society
Verified
Journal Article
Open access
PDF file
SOSABITU OLASUPO
SABITU OLASUPO
AUAdamu Uzairu
Adamu Uzairu
GSGideon Shallangwa
Gideon Shallangwa
SUSani Uba
Sani Uba
Chemometrics study that relates biological activity to physicochemical descriptors of a molecule and the prediction of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties in advance are important steps in drugs discovery. In this study, a chemometrics approach was employed on some molecules (inhibitors) of norepinephrine transporter to assess their inhibitory potencies, interactions with the receptor and predict their ADMET/pharmacokinetic properties for identification of novel antipsychotic drugs. The molecules were optimized by using density functional theory at the basis set of B3LYP/6-31G*. The genetic function algorithm technique was used to generate a statistically significant model with a good correlation coefficient R2Train = 0.952 Cross-validated coefficient Q2cv = 0.870, and adjusted squared correlation coefficient R2adj = 0.898. The molecular docking simulation using a neurotransmitter transporter receptor (PDB Code 2A65) revealed that three inhibitors (molecule No 38, 44 and 12) exhibited the highest binding affinity of − 10.3, − 9.9 and − 9.3 kcal/mol, respectively, were observed to inhibit the target by forming strong hydrogen bonds with hydrophobic interactions. The physicochemical and ADMET/pharmacokinetic properties result showed that these three molecules are orally bioavailable, high gastrointestinal absorption, good permeability and non-inhibitors of CYP3A4 and CYP2D6 except for molecule No 38. Also, Molecules No 38 and 44 proved to be non-substrate of P-glycoprotein and nontoxicity to a human ether-a-go-go-related gene with predicted hERG toxicity endpoints (pIC50 < 6) and low ADMET_Risk (< 7.0). The results of this study would provide physicochemical and pharmacokinetics properties needed to identify potent antipsychotic drugs and other relevant information in drug discovery.

10 March 2021 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
SOSABITU OLASUPO
SABITU OLASUPO
AUAdamu Uzairu
Adamu Uzairu
GSGideon Adamu Shallangwa
Gideon Adamu Shallangwa
SUSani Uba
Sani Uba
Background The inhibition of dopamine transporter is known to play a significant role in the treatment of schizophrenia-related and other mental disorders. In a continuing from our previous study, computational drug design approach, molecular docking simulation, and pharmacokinetics study were explored for the identification of novel inhibitors dopamine transporter as potential Antischizophrenic agents. Consequently, thirteen (13) new inhibitors of dopamine transporter were designed by selecting the molecule with serial number 39 from our previous study as the template molecule because it exhibits good pharmacological attributes. Results Molecular docking simulation results revealed excellent molecular interactions between the protein target (PDB: 4m48) and the ligands (designed inhibitors) with major interactions that involved hydrogen bonding and hydrophobic interactions. Also, some of the designed inhibitors displayed a superior binding affinity range from − 10.0 to − 10.7 kcal/mol compared to the referenced drug (Lumateperone) with a binding affinity of − 9.7 kcal/mol. Computed physicochemical parameters showed that none of the designed inhibitors including the referenced drug violate Lipinski’s rule of five indicating that all the designed inhibitors would be orally bioavailable as potential drug candidates. Similarly, the ADMET/pharmacokinetics evaluations of some designed inhibitors revealed that they possessed good absorption, distribution, metabolism and excretion properties and none of the inhibitors is neither carcinogens nor toxic toward human ether-a-go-go related gene (hERG I) inhibitor or skin sensitization. Likewise, the BOILED-Egg graphics unveils that all the designed inhibitors demonstrate a high probability to be absorbed by the human gastrointestinal tract and could permeate into the brain. Besides, the predicted bioactive parameters suggested that all the selected inhibitors would be active as drug candidates. Furthermore, the synthetic accessibility scores for all the selected inhibitors and referenced drug lied within the easy zone (i.e., between 1–4) with their computed values range from 2.55 to 3.92, this implies that all the selected inhibitors would be very easy to synthesize in the laboratory. Conclusions Hence, all the designed inhibitors having shown excellent pharmacokinetics properties and good bioavailabilities attributes with remarkable biochemical interactions could be developed and optimized as novel Antischizophrenic agents after the conclusion of other experimental investigations.

1 July 2020 in Heliyon
Verified
Journal Article
Open access
SOSABITU OLASUPO
SABITU OLASUPO
AUAdamu Uzairu
Adamu Uzairu
GSGideon Adamu Shallangwa
Gideon Adamu Shallangwa
SUSani Uba
Sani Uba
Chemoinformatic studies were carried on some inhibitors of dopamine transporter to develop a predictive and robust QSAR model and also to elucidate binding mode and molecular interactions between the ligands (inhibitors) and the receptor targeting schizophrenia as novel Antipsychotic agents. Density Functional Theory (DFT) approach was utilized to optimize the ligands at B3LYP/6-31G∗ at the ground state and Multi-linear regression of the genetic function approximation (MLR-GFA) method was employed in building Penta-parametric linear equation models. The best model with statistically significant parameters has squared correlation coefficient R2= 0.802, adjusted squared correlation coefficient R2adj = 0.767, Leave one out (LOO) cross-validation coefficient (Q2) = 0.693, lack of fit score (LOF) = 0.406, R2Test = 0.77, Y-randomization test (cR2p) = 0.714, Chi-squared (χ2) =0.026, bootstrapping (Systematic errors = 0.272) and Variance Inflation Factor (VIF) <2 . The obtained results were compared with standard validation parameters to ascertain the predictivity, reliability, and robustness of the model. Also, the mechanistic interpretation of the descriptors found in the model revealed that two out of five descriptors; MATS7s (32.3%) and RDF95m (30.4%) having pronounced influence on the observed antipsychotic property of the compounds evidenced by their highest percentage contributions. More so, the molecular docking investigation showed that the binding affinity of the selected ligands ranges from -10.05 to -9.0 kcal/mol and with ligand 21 possessed the highest binding affinity (-10.05 kcal/mol). Furthermore, all the selected ligands displayed hydrogen bonds and hydrophobic interactions with the amino acid residues of the target (4M48) which could account for their higher binding energy. Our findings revealed that the developed model passed the general requirements for an acceptable QSAR model and also satisfied the OECD principles for model development. Hence, the developed model would be practically useful as a blueprint in developing novel antipsychotic agents with improved activity for the treatment of schizophrenia mental disorder.


15 February 2020 in Journal of the Turkish Chemical Society Section A: Chemistry
Verified
Journal Article
Open access
PDF file
SOSABITU OLASUPO
SABITU OLASUPO
AUAdamu Uzairu
Adamu Uzairu
GSGideon Shallangwa
Gideon Shallangwa
SUSani Uba
Sani Uba
The Norepinephrine transporter (NET) is a Na+/Cl- coupled neurotransmitter transporter responsible for reuptake of released norepinephrine (NE) into neural terminals in the brain, an important therapeutic agent used in the treatment of psychiatric disorders. A quantitative structural activity relationship (QSAR) investigation was carried out on 50 Molecules of NET Inhibitors to investigate their inhibitory potencies against norepinephrine transporter as novel agents for anti-psychotic disorders. The molecules were optimized by employing Density functional theory (DFT) with basis set of B3LYP/6-31G*. The genetic function Algorithm (GFA) approach was used to generate a highly predictive and statistically significant model with good correlation coefficient R2 Train = 0.952, Cross validated coefficient Q2cv = 0.870 and adjusted squared correlation coefficient R2adj = 0.898. The predictability and accuracy of the developed model was evaluated through external validation using test set molecules, Y-randomization and applicability domain techniques. The results of Molecular docking simulation by using two neurotransmitter transporters PDB ID 2A65 (resolution = 1.65 Å ) and PDB ID 4M48 (resolution = 2.955 Å) showed that two of the ligands (compound numbers 12 and 44) having higher binding affinity were observed to inhibit the targets by forming hydrogen bonds and hydrophobic interactions with amino acids of the two receptors respectively. The results of this study are envisaged to provide very important new insights into the molecular basis and structural requirements that would help in designing more potent and more specific therapeutic anti-psychotic agents.

23 March 2025 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
SEStephen Ejeh
Stephen Ejeh
AAAbduljelil Ajala
Abduljelil Ajala
SASAMUEL ADAWARA
SAMUEL ADAWARA
SOSABITU OLASUPO
SABITU OLASUPO
ZIZakari Ya'u Ibrahim
Zakari Ya'u Ibrahim
UAUsman Abdulfatai
Usman Abdulfatai
One of the most prevalent genetic conditions is sickle cell disease (SCD), a multiorgan condition that impacts about 15 million people around the globe. The current standard of care for SCD mainly consists of hydroxyurea therapy or supportive care, which includes hydration, blood transfusions, and pain control. The FDA recently approved strategies that lower the frequency of vaso-occlusive crisis (VOC) events, including the monoclonal P-selectin and the small molecule L-glutamine. The search for drugs that bind to Hb and alter the oxygenation state allostery has been a key therapeutic area for SCD. In this study, computational methods such as in silico screening, pharmacokinetic evaluation, DFT study, and molecular dynamic simulation were used to identify lead compounds as natural antisickling agents. The idea was to search PubChem databases for novel bioactive plant compounds with the potential to prevent SCD effectively. The PubChem databases were screened based on the binding energy (BE), pharmacokinetics properties, DFT study, and MD simulation, and 3 molecules with PUBCHEM_CID 20684853, 44461326, and 137225065 out of the 157 compounds examined were identified as active candidate hits with BE of − 177.35 kcal, − 175.11 kcal, and − 182.13 kcal, respectively, as compared to − 173.08 kcal of P-Selectin, which indicated that it is more stable and requires more energy to dissociate. When compared to P-Selectin as the standard drug, these molecules showed the best pharmacokinetic properties and potency.